BRPI0706114A2 - composto de sal de acido tartÁrico de isofagomina (tartarato de isofagomina), complexo, composiÇço, mÉtodo para preparar tartarato de isofagomina, composiÇço farmacÊutica, composto, mÉtodo para tratar doenÇa de gaucher, mÉtodo para aumentar a atividade da glucocerebrosidase e sal de isofagomina - Google Patents
composto de sal de acido tartÁrico de isofagomina (tartarato de isofagomina), complexo, composiÇço, mÉtodo para preparar tartarato de isofagomina, composiÇço farmacÊutica, composto, mÉtodo para tratar doenÇa de gaucher, mÉtodo para aumentar a atividade da glucocerebrosidase e sal de isofagominaInfo
- Publication number
- BRPI0706114A2 BRPI0706114A2 BRPI0706114-5A BRPI0706114A BRPI0706114A2 BR PI0706114 A2 BRPI0706114 A2 BR PI0706114A2 BR PI0706114 A BRPI0706114 A BR PI0706114A BR PI0706114 A2 BRPI0706114 A2 BR PI0706114A2
- Authority
- BR
- Brazil
- Prior art keywords
- isofagomine
- compound
- tartrate
- salt
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cephalosporin Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
COMPOSTO DE SAL DE ÁCIDO TARTÁRICO DE ISOFAGOMINA (TARTARATO DE ISOFAGOMINA), COMPLEXO, COMPOSIÇçO, MÉTODO PARA PREPARAR TARTARATO DE ISOFAGOMINA, COMPOSIÇçO FARMACÊUTICA, COMPOSTO, MÉTODO PARA TRATAR DOENÇA DE GAUCHER, MÉTODO PARA AUMENTAR A ATIVIDADE DA GLUCOCEREBROSIDASE E SAL DE ISOFAGOMINA. Um novo sal de ácido tartárico de isofagomina (tartarato de isofagomina) que pode ser utilizado para o tratamento da doença de Gaucher é provido. A invenção também provê uma forma cristalina do tartarato de isofagomina, um método para preparar o sal, uma composição farmacêutica contendo o sal, e um método para tratar a doença de Gaucher
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80802006P | 2006-05-24 | 2006-05-24 | |
| US89071907P | 2007-02-20 | 2007-02-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0706114A2 true BRPI0706114A2 (pt) | 2008-11-18 |
Family
ID=38462442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0706114-5A BRPI0706114A2 (pt) | 2006-05-24 | 2007-05-24 | composto de sal de acido tartÁrico de isofagomina (tartarato de isofagomina), complexo, composiÇço, mÉtodo para preparar tartarato de isofagomina, composiÇço farmacÊutica, composto, mÉtodo para tratar doenÇa de gaucher, mÉtodo para aumentar a atividade da glucocerebrosidase e sal de isofagomina |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7501439B2 (pt) |
| EP (1) | EP1860101B1 (pt) |
| JP (1) | JP5292605B2 (pt) |
| AT (1) | ATE504570T1 (pt) |
| AU (1) | AU2007202359B2 (pt) |
| BR (1) | BRPI0706114A2 (pt) |
| CA (1) | CA2590122C (pt) |
| DE (1) | DE602007013648D1 (pt) |
| DK (1) | DK1860101T3 (pt) |
| IL (1) | IL183415A (pt) |
| MX (1) | MX2007006175A (pt) |
| PL (1) | PL1860101T3 (pt) |
| PT (1) | PT1860101E (pt) |
| WO (1) | WO2007140212A2 (pt) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2485369T3 (es) * | 2005-06-08 | 2014-08-13 | Amicus Therapeutics, Inc. | Tratamiento de trastornos del SNC asociados con mutaciones en genes que codifican enzimas lisosómicas |
| BRPI0713442A2 (pt) | 2006-06-23 | 2012-03-06 | Amicus Therapeutics, Inc. | Método para o tratamento de desrodens neurológicas, pelo aumento da atividade de b-glicocerebrosidase |
| AU2008254594B2 (en) | 2007-05-22 | 2013-06-27 | Amicus Therapeutics, Inc. | New method for preparing isofagomine and its derivatives |
| EP3470077B1 (en) | 2008-02-12 | 2020-08-26 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| GB2480159A (en) * | 2008-11-14 | 2011-11-09 | Parkinson S Inst | Compositions and methods for the treatment of altered a-synuclein function |
| AU2010281403B2 (en) | 2009-07-28 | 2016-03-10 | Takeda Pharmaceutical Company Limited | Compositions and methods for treating Gaucher disease |
| PT2490532T (pt) | 2009-10-19 | 2017-02-23 | Amicus Therapeutics Inc | Novas composições para a prevenção e/ou tratamento de distúrbios degenerativos do sistema nervoso central |
| PT2995306T (pt) * | 2009-10-19 | 2019-03-29 | Amicus Therapeutics Inc | Novas composições para prevenção e/ou tratamento de disfunções de armazenamento lisossomal |
| HUE044867T2 (hu) | 2011-05-12 | 2019-11-28 | Proteostasis Therapeutics Inc | Proteosztázis szabályzók |
| CN103764166B (zh) | 2011-06-22 | 2017-10-24 | 通用医疗公司 | 蛋白质病的治疗 |
| WO2013112706A1 (en) | 2012-01-25 | 2013-08-01 | Proteostasis Therapeutics, Inc. | Proteasome activity modulating compounds |
| MX361231B (es) | 2012-03-02 | 2018-11-30 | Shire Human Genetic Therapies | Composiciones y usos de las mismas para tratar la enfermedad de gaucher tipo iii. |
| MX354127B (es) | 2012-03-27 | 2018-02-14 | Amicus Therapeutics Inc | Compuestos novedosos para prevenir y/o tratar tesaurismosis lisosomicas y/o trastornos degenerativos del sistema nervioso central. |
| US9464035B2 (en) | 2012-03-28 | 2016-10-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Salicylic acid derivatives useful as glucocerebrosidase activators |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| DE102017103346A1 (de) * | 2017-02-17 | 2018-08-23 | Lts Lohmann Therapie-Systeme Ag | Strukturierte orodispergierbare Filme |
| CA3078463A1 (en) * | 2017-10-26 | 2019-05-02 | Shire Human Genetic Therapies, Inc. | Formulations comprising glucocerebrosidase and isofagomine |
| MA53014A (fr) | 2018-06-27 | 2021-05-05 | Proteostasis Therapeutics Inc | Composés améliorant l'activité du protéasome |
| WO2020006269A1 (en) | 2018-06-27 | 2020-01-02 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| WO2020023390A1 (en) | 2018-07-25 | 2020-01-30 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| US20230110129A1 (en) * | 2019-04-25 | 2023-04-13 | Takeda Pharmaceutical Company Limited | Isofagomine salts, methods of use and formulations |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5844102A (en) | 1994-07-07 | 1998-12-01 | University Of Maryland Baltimore County | Glycohydrolase inhibitors, their preparation and use thereof |
| US6274597B1 (en) * | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
-
2007
- 2007-05-23 WO PCT/US2007/069550 patent/WO2007140212A2/en active Application Filing
- 2007-05-23 AT AT07252109T patent/ATE504570T1/de active
- 2007-05-23 DK DK07252109.9T patent/DK1860101T3/da active
- 2007-05-23 US US11/752,658 patent/US7501439B2/en active Active
- 2007-05-23 PT PT07252109T patent/PT1860101E/pt unknown
- 2007-05-23 DE DE602007013648T patent/DE602007013648D1/de active Active
- 2007-05-23 PL PL07252109T patent/PL1860101T3/pl unknown
- 2007-05-23 EP EP07252109A patent/EP1860101B1/en active Active
- 2007-05-23 MX MX2007006175A patent/MX2007006175A/es active IP Right Grant
- 2007-05-24 IL IL183415A patent/IL183415A/en active IP Right Grant
- 2007-05-24 BR BRPI0706114-5A patent/BRPI0706114A2/pt not_active Application Discontinuation
- 2007-05-24 JP JP2007138358A patent/JP5292605B2/ja not_active Expired - Fee Related
- 2007-05-24 AU AU2007202359A patent/AU2007202359B2/en not_active Ceased
- 2007-05-24 CA CA 2590122 patent/CA2590122C/en not_active Expired - Fee Related
-
2009
- 2009-02-23 US US12/391,049 patent/US7863453B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DE602007013648D1 (de) | 2011-05-19 |
| ATE504570T1 (de) | 2011-04-15 |
| AU2007202359B2 (en) | 2012-02-16 |
| US20090176830A1 (en) | 2009-07-09 |
| CA2590122C (en) | 2015-03-31 |
| US7863453B2 (en) | 2011-01-04 |
| AU2007202359A1 (en) | 2007-12-13 |
| IL183415A (en) | 2012-03-29 |
| EP1860101A1 (en) | 2007-11-28 |
| IL183415A0 (en) | 2007-09-20 |
| JP5292605B2 (ja) | 2013-09-18 |
| PL1860101T3 (pl) | 2011-10-31 |
| WO2007140212A3 (en) | 2008-12-24 |
| EP1860101B1 (en) | 2011-04-06 |
| CA2590122A1 (en) | 2007-11-24 |
| DK1860101T3 (da) | 2011-07-25 |
| US20070281975A1 (en) | 2007-12-06 |
| MX2007006175A (es) | 2009-02-16 |
| JP2007314540A (ja) | 2007-12-06 |
| US7501439B2 (en) | 2009-03-10 |
| WO2007140212A2 (en) | 2007-12-06 |
| PT1860101E (pt) | 2011-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0706114A2 (pt) | composto de sal de acido tartÁrico de isofagomina (tartarato de isofagomina), complexo, composiÇço, mÉtodo para preparar tartarato de isofagomina, composiÇço farmacÊutica, composto, mÉtodo para tratar doenÇa de gaucher, mÉtodo para aumentar a atividade da glucocerebrosidase e sal de isofagomina | |
| ATE530519T1 (de) | Cyclobutylaminderivate | |
| ATE523504T1 (de) | 1-thio-d-glucitolderivate | |
| PL1960379T3 (pl) | Pochodne N-(1-alkilo-2-fenyloetylo)-karboksamidu i ich zastosowanie jako fungicydów | |
| WO2007140174A3 (en) | Compounds and methods for modulating fxr | |
| NZ607794A (en) | N-acylsulfonamide apoptosis promoters | |
| PE20150998A1 (es) | Inhibidores de histona demetilasas | |
| PL1761522T3 (pl) | Związki i sposoby leczenia dyslipidemii | |
| NO20085068L (no) | Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
| EA200970296A1 (ru) | Содержащие диариловый эфир соединения мочевины | |
| NO20075111L (no) | Farmasoytisk sammensetning | |
| UA87250C2 (ru) | Применение соединений пиперазина как гербицидов, средство, способ его получения и способ борьбы с нежелательным ростом растительности, соединения пиперазина, способ их получения (варианты) и промежуточные соединения | |
| TW200637828A (en) | Novel cis-imidazolines | |
| BRPI0514715A (pt) | composições farmacêuticas compreendendo ácido 4-(4-(3-(4-cloro-3-trifluormetilfenil)-ureìdo)-3-fluorf enóxi)-piridina-2-carboxìlico para o tratamento de desordens hiperproliferativas | |
| NO20081905L (no) | Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander | |
| BRPI0915942A2 (pt) | método para produção de compostos medicinais contendo dabigatrana | |
| BRPI0715531A2 (pt) | Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto | |
| BRPI0918580A8 (pt) | Polimorfo cristalino b da n-(2-aminofenil)-4-[n-(piridina3-il)metóxi-carbonilaminometil]-benzamida, composição e combinação contendo o mesmo, uso e seu processo de produção | |
| EP2103214A4 (en) | FLOOR OR SEED TREATMENT AGENT CONTAINING A CHINOLINE COMPOUND OR A SALT THEREOF AS ACTIVE SUBSTANCE OR METHOD FOR COMBATING PLANT DISEASES USING THE AGENT | |
| PE20120898A1 (es) | Inhibidores de dihidroorotato deshidrogenasa como compuestos virostaticos | |
| BRPI0614363A2 (pt) | formulação de concentração emulsificável, processo para preparar uma formulação de ec, de uma formulação de ec, e, método para controlar pestes de insetos | |
| IL183373A0 (en) | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof | |
| BRPI0515441B8 (pt) | compostos ácidos 4-((fenoxialquil)tio)-fenoxiacéticos e análogos, bem como composição farmacêutica que os compreende | |
| NO20063859L (no) | Cykloalkylsubstituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og anvendelse derav som medikamenter | |
| WO2008062436A3 (en) | Antimicrobial derivatives of anacardic acid and process for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |